Writing · Category
Peptide Therapy
Plain, evidence-grounded explanations of the questions patients bring to the practice, written by the physician who treats them.
DSIP Peptide for Sleep: What a Psychiatrist Makes of Delta Sleep-Inducing Peptide
DSIP peptide arrives with a name that sounds like a promise: delta sleep-inducing peptide. Unlike a lot of what gets sold online, it has an actual human research record behind it, one that goes back to the 1970s…
The FDA Peptide Decision of July 2026: What’s Actually Changing
On July 23 and 24, 2026, an FDA advisory committee spent two days deciding whether seven peptides can be legally compounded for patients. Three of them, Semax, Epitalon, and BPC-157, are the ones I get asked about most…
Peptide Therapy With SSRIs and Stimulants: What a Psychiatrist Wants You to Know
Published: April 2026 | By: Dr. Baghel | Category: Peptide Therapy, Adult Psychiatry For where peptide regulation is heading, see my explainer on the 2026 FDA peptide compounding vote. Not every peptide patients ask about is one I…
Psychiatrist Sleep Medication Guide: Prescription Drugs, Peptides, and Supplements
Sleep problems are one of the most common reasons patients come to a psychiatrist. Not because they tried a supplement and it failed, though many have. Finding the right psychiatrist sleep medication, peptide, or supplement is rarely about…
Epitalon, Sleep, and the Aging Brain: What a Psychiatrist Wants You to Know
Update, July 24, 2026: The FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding epitalon to the 503A compounding list, and the indication it voted on was insomnia. STAT News reported the tally as 7-4. RAPS Regulatory Focus…
GLP-1 Medications and Mental Health: What Your Psychiatrist Wants You to Know About Ozempic, Mounjaro, and Beyond
GLP-1 drugs like Ozempic and Mounjaro are known for weight and blood sugar. They also act on the brain, which makes them a psychiatric concern. Millions of patients are now on GLP-1 receptor agonists for diabetes and weight…
BPC-157: What It Is, How It Works, and What the Research Actually Shows
Published: March 2026 | By: Dr. Baghel | Category: Peptide Therapy BPC-157 was one of seven peptides the FDA reviewed for its compounding list in 2026. I put its human evidence next to the other six in the…
Peptides vs SSRIs for Depression and Anxiety: Expert Psychiatrist Explains
Published: March 19, 2026 | By: Dr. Baghel | Category: Peptide Therapy Peptides vs SSRIs Depression Anxiety: A Psychiatrist Who Prescribes Both Explains The internet has decided that peptides and SSRIs are enemies. Wellness influencers frame it as…
Semax and Selank for Anxiety, Depression, PTSD, and Cognition
Published: March 16, 2026 | By: Dr. Baghel | Category: Peptide Therapy Update, July 24, 2026: An FDA advisory committee voted, as reported, to recommend adding semax to the 503A compounding list. Read the indication before the headline.…
Peptide Therapy in North Carolina: What the RFK Jr. Announcement Means for Patients
By Dr. Shantanu Baghel, Board-Certified Psychiatrist | Baghel Psychiatry | February 2026 An FDA advisory committee met on July 23-24, 2026 to weigh seven of these peptides. I covered the vote and graded the evidence in this analysis. Update,…